Quantbot Technologies’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,219
| Closed | -$315K | – | 2006 |
|
|
2025
Q4 | $315K | Sell |
2,219
-1,642
| -43% | -$238K | 0.01% | 1097 |
|
|
2025
Q3 | $542K | Sell |
3,861
-2,145
| -36% | -$291K | 0.01% | 991 |
|
|
2025
Q2 | $755K | Buy |
+6,006
| New | +$689K | 0.02% | 878 |
|
|
2024
Q4 | – | Sell |
-769
| Closed | -$88.6K | – | 1706 |
|
|
2024
Q3 | $88.6K | Buy |
+769
| New | +$105K | ﹤0.01% | 1190 |
|
|
2024
Q2 | – | Sell |
-26
| Closed | -$3.59K | – | 1757 |
|
|
2024
Q1 | $3.59K | Sell |
26
-1,665
| -98% | -$227K | ﹤0.01% | 1489 |
|
|
2023
Q4 | $223K | Sell |
1,691
-538
| -24% | -$61.9K | 0.01% | 982 |
|
|
2023
Q3 | $251K | Buy |
2,229
+1,581
| +244% | +$166K | 0.02% | 837 |
|
|
2023
Q2 | $61.1K | Buy |
648
+52
| +9% | +$5.08K | ﹤0.01% | 1284 |
|
|
2023
Q1 | $60.3K | Sell |
596
-3,029
| -84% | -$315K | ﹤0.01% | 1217 |
|
|
2022
Q4 | $433K | Buy |
+3,625
| New | +$425K | 0.03% | 628 |
|
|
2022
Q3 | – | Sell |
-1,411
| Closed | -$137K | – | 1910 |
|
|
2022
Q2 | $137K | Buy |
+1,411
| New | +$130K | 0.01% | 1055 |
|
|
2022
Q1 | – | Sell |
-3,447
| Closed | -$293K | – | 1919 |
|
|
2021
Q4 | $293K | Buy |
3,447
+2,943
| +584% | +$271K | 0.02% | 646 |
|
|
2021
Q3 | $48K | Buy |
+504
| New | +$47.6K | ﹤0.01% | 1115 |
|
|
2021
Q1 | – | Sell |
-105
| Closed | -$10K | – | 1643 |
|
|
2020
Q4 | $10K | Sell |
105
-5,654
| -98% | -$546K | ﹤0.01% | 1105 |
|
|
2020
Q3 | $553K | Buy |
5,759
+4,580
| +388% | +$530K | 0.06% | 330 |
|
|
2020
Q2 | $143K | Buy |
1,179
+1,079
| +1,079% | +$119K | 0.02% | 509 |
|
|
2020
Q1 | $8K | Sell |
100
-5,997
| -98% | -$587K | 0.01% | 714 |
|
|
2019
Q4 | $655K | Buy |
6,097
+3,258
| +115% | +$341K | 0.07% | 349 |
|
|
2019
Q3 | $255K | Buy |
2,839
+639
| +29% | +$59.7K | 0.03% | 638 |
|
|
2019
Q2 | $185K | Sell |
2,200
-1,613
| -42% | -$132K | 0.02% | 616 |
|
|
2019
Q1 | $335K | Buy |
3,813
+3,235
| +560% | +$270K | 0.03% | 542 |
|
|
2018
Q4 | $41K | Sell |
578
-1,349
| -70% | -$129K | ﹤0.01% | 847 |
|
|
2018
Q3 | $236K | Buy |
+1,927
| New | +$219K | 0.02% | 709 |
|
|
2017
Q2 | – | Sell |
-1,581
| Closed | -$68K | – | 1278 |
|
|
2017
Q1 | $68K | Buy |
+1,581
| New | +$67.7K | 0.01% | 865 |
|
|
2015
Q4 | – | Sell |
-2,141
| Closed | -$85K | – | 1271 |
|
|
2015
Q3 | $85K | Sell |
2,141
-610
| -22% | -$29.5K | 0.01% | 797 |
|
|
2015
Q2 | $131K | Buy |
+2,751
| New | +$117K | 0.02% | 565 |
|
|
2014
Q4 | – | Sell |
-4,469
| Closed | -$70K | – | 1309 |
|
|
2014
Q3 | $70K | Sell |
4,469
-603
| -12% | -$9.01K | 0.01% | 926 |
|
|
2014
Q2 | $75K | Buy |
+5,072
| New | +$71.6K | 0.01% | 833 |
|
Other funds holding NBIX
Quantbot Technologies's NBIX Position: Q1 2026 in Review
Quantbot Technologies sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 2,219 shares — an estimated $315K sold.
Quantbot Technologies first reported a position in NBIX in Q2 2014 and held it in 28 quarters. The position peaked at $755K in Q2 2025. 699 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Quantbot Technologies reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
- Quantbot Technologies sold 2,219 Neurocrine Biosciences shares in Q1 2026, an estimated $315K.
- Quantbot Technologies first reported a position in Neurocrine Biosciences in Q2 2014 and held it in 28 quarters.
- Quantbot Technologies's Neurocrine Biosciences position peaked at $755K in Q2 2025.
- 699 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Quantbot Technologies's 13F filing for Q1 2026, filed 13 May 2026.